Summary
ProShares Ultra Nasdaq Biotechnology is an ETF - a fund traded on an exchange like a stock - run by ProShares. Positions inside: 256. The ten largest make up 64% of the fund.
- Yearly costs
- 1.17%
- Fund size
- $88.5M
- Positions
- 256
- Dividend yield
- 0.08%
- Running since
- 2010
What speaks for it
- Average yearly growth over the last ten years: 9.8%.
- It has been running since 2010.
What to watch
- The ten largest positions make up 64% of the fund, so its result rests on a few names.
- 63% of the fund is in one sector (Healthcare).
- Costs of 1.17% a year are above the middle of comparable funds (0.44%).
- In the last five years its price once dropped by 67% from its high.
- A small fund with $88.5M under management; small funds get closed more often.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -3.5%
- 3 months
- +11%
- This year
- +34%
- 1 year
- +56%
- 3 years
- +144%
- 5 years
- +21%
- 10 years
- +155%
- Avg. market cap
- $81.9B
- P/E
- 26.9x
- Forward P/E
- 19.3x
- P/S
- 6.9x
- P/B
- 5.9x
- P/FCF
- 19.7x
- EV/EBITDA
- 20.6x
- Dividend yield
- 0.64%
- ROIC
- -2.8%
- ROE
- 8.1%
- Gross margin
- 71.8%
- Operating margin
- -405.8%
- Net margin
- -97.7%
- Payout ratio
- 17.1%
- Net debt/EBITDA
- 6.1x
- Beta
- 1.20
Weighted average of the 50 largest companies, which make up 51% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 IQProShares - GENIUS Money Market ETF IQMM 19%
- 2 Net Other Assets (Liabilities) 17%
- 3 GIGilead Sciences GILD 5.7%
- 4 AMAmgen AMGN 5.3%
- 5 VRVertex Pharmaceuticals VRTX 4.9%
- 6 MRModerna MRNA 3.8%
- 7 RERegeneron Pharmaceuticals REGN 3.5%
- 8 ILIllumina ILMN 1.7%
- 9 RVRevolution Medicines RVMD 1.7%
- 10 BIBiogen BIIB 1.5%
Positions in the fund: 256. The ten largest make up 64% of it.
Composition as of Oct 18, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 63%
- Financials 19%
- Other 18%
By country
- United States 76%
- United Kingdom 1.5%
- Netherlands 1.2%
- Ireland 1.0%
- Other countries 20%
By company size
- Mega cap 8.4%
- Large cap 63%
- Mid cap 21%
- Small cap 7.3%
- Micro cap 0.5%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M. Counted from the companies that make up 63% of the fund.
Largest sector: Healthcare (63%). Largest country: United States (76%). Largest size group: Large cap (63%).
What does it cost me?
Expensive- A year from $10,000
- $117
- Over 20 years
- $5,327
From every $10,000 invested the fund takes $117 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $5,327.
How has it done?
Growing over the long run- A year on average, 10 years
- +9.8%
- Deepest drop
- -67%
- Yearly volatility
- 44%
Average yearly growth over the last ten years: 9.8%. Deepest drop in these years: 67% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 0.08%
- Payments a year
- 4
- Last payment
- $0.08
Over the last 12 months it paid $0.09 per share, which is 0.08% of today's price. The last payment was $0.08 on Sep 23, 2026.
Is it easy to buy and sell?
Yes- Traded a day
- $1.18M
- Shares a day
- 11K
On an average day about $1.18M of the fund changes hands.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 26.9
- Average Bulios Score
- 52 out of 100
Weight by Bulios Fair Price
- Undervalued 33%
- Fairly valued 16%
- Overvalued 51%
On average the companies inside trade for 26.9 times their yearly profit. By Fair Price, 51% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 51% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $906.2M | +37% | Reinvests | 63% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $79.9M | +30% | Pays out | 63% |
SB SBIO.MI Invesco NASDAQ Biotech UCITS ETF | Ireland | 0.40% | $568.8M | +37% | Reinvests | 62% |
20 203780.KS MiraeAsset TIGER NASDAQ BIO ETF | South Korea | 0.30% | $76.4M | +22% | Reinvests | 62% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.5B | +30% | Pays out | 57% |
BB BBH VanEck Biotech ETF | United States | 0.35% | $486.7M | +35% | Pays out | 37% |
